Table 3 Genotype frequencies: MTHFR A1298C

All patients

244 (42.9%)

268 (47.1%)

54 (9.5%)

Status

Alive

152 (45.1%)

149 (44.2%)

36 (10.7%)

Dead

92 (40.2%)

119 (52.0%)

18 (7.9%)

Sex

Male

184 (43.0%)

204 (47.1%)

40 (9.3%)

Female

60 (43.5%)

64 (46.4%)

14 (10.1%)

Localization

AEG

152 (43.7%)

164 (47.1%)

32 (9.2%)

UICC 7th edtition

Gastric cancer

87 (41.0%)

103 (48.6%)

22 (10.4%)

Localization

AEG I

60 (42.6%)

68 (48.2%)

13 (9.2%)

UICC 6th edition

AEG II/III + GC

184 (43.3%)

200 (47.1%)

41 (9.6%)

Laurén

Intestinal

140 (44.0%)

150 (47.2%)

28 (8.8%)

Non-intestinal

100 (42.9%)

109 (46.8%)

24 (10.3%)

Grading

Low grade

70 (42.4%)

77 (46.7%)

18 (10.9%)

High grade

172 (43.8%)

186 (47.3%)

35 (8.9%)

pT

pT0

16 (42.1%)

18 (47.4%)

4 (10.5%)

pT1

17 (33.3%)

28 (54.9%)

6 (11.8%)

pT2

119 (43.3%)

125 (45.5%)

31 (11.3%)

pT3

83 (45.4%)

88 (48.1%)

12 (6.6%)

pT4

9 (47.4%)

9 (47.4%)

1 (5.3%)

pN

pN0

98 (40.7%)

118 (49.0%)

25 (10.4%)

pN1

97 (48.5%)

84 (42.0%)

19 (9.5%)

pN2

30 (41.1%)

37 (50.7%)

6 (8.2%)

pN3

9 (32.1%)

16 (57.1%)

3 (10.7%)

pNx

10 (41.7%)

13 (54.2%)

1 (4.2%)

pM

pM0

226 (43.3%)

244 (46.7%)

52 (10.0%)

pM1

18 (40.9%)

24 (54.5%)

2 (4.5%)

R

R0

199 (42.0%)

226 (47.7%)

49 (10.3%)

R1/R2

45 (48.9%)

42 (45.7%)

5 (5.4%)

Neoadjuvant chemotherapy

Yes

156 (42.6%)

179 (48.9%)

31 (8.5%)

No

88 (44.0%)

89 (44.5%)

23 (11.5%)

Clinical response

Responder

46 (43.8%)

49 (46.7%)

10 (9.5%)

Nonresponder

109 (41.9%)

130 (50.0%)

21 (8.1%)

TRG

1a,1b

41 (39.4%)

55 (52.9%)

8 (7.7%)

2,3

114 (43.8%)

123 (47.3%)

23 (8.8%)